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ABSTRACT
Background: Small studies have suggested that nucleos(t)ide analogue therapy (NAT) 
with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in pre-
venting post-liver transplantation (LT) HBV recurrence. 
Objectives: This larger study evaluates the use of NAT with short term (< 6 mo) or no 
HBIG for prevention of post-LT HBV recurrence.
Patients and Methods: All HBV patients undergoing LT at a university transplant center 
between 2002 and 2007 were identified retrospectively. Patient demographics, medi-
cation regimen, and adverse events were noted. The primary endpoint was HBV recur-
rence and secondary endpoints were graft and patient survival. 
Results: 28 study patients were identified. Of these 28 patients, 4 (14%) received no 
HBIG, 6 (22%) received only inpatient HBIG, and 18 (64%) received inpatient HBIG and 
outpatient HBIG. 16 of the 28 patients (57%) received combination NAT and 12 patients 
(43%) received single NAT. At a median time of 15.5 months (range 9–24 months) post-
LT, 4 of the 28 patients (14%) had recurrent HBV. Of those patients with recurrent HBV, 
3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV 
recurrence were associated with noncompliance. 
Conclusions: NAT with short-term or no HBIG was efficacious and safe in preventing 
post-LT HBV. All compliant patients were HBV-free, including 9 patients who received 
no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear 
justified. 
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  Implication for health policy/practice/research/medical education:
Hepatitis B viral infection is a worldwide problem affecting 400 million people. The advent of hepatitis B immunoglobulin and an-
tiviral therapy has reduced the risk of hepatitis B recurrence in liver transplant patients. In this article, we highlight the importance 
of compliance to these therapies and provide further data that with potent, newer HBV antiviral therapies, the shift away from long 
term hepatitis B immunoglobulin has begun.
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1. Background
The number of patients with hepatitis B (HBV) listed 
for liver transplantation (LT) in the United States 
has decreased by 37% since 2000, presumably due to 
the availability of effective oral antiviral therapy (1). 
However, the more than 350 million people infected 
worldwide continue to make HBV and associated 
hepatocellular carcinoma important indications for 
liver transplantation. Therefore, prevention of HBV 
recurrence in patients undergoing LT will remain an 
important challenge worldwide. Historically, many 
transplant centers have been reluctant to offer LT for Hepat Mon. 2011;11(8):638-645
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HBV patients due to the high risk of recurrence leading 
to graft failure, increased patient mortality, and the 
need for re-transplantation. After the protective ability 
of long-term, high-dose hepatitis B immunoglobulin 
(HBIG) was recognized, however, HBV became an 
accepted indication for LT (2). HBIG is expensive and 
carries an HBV recurrence risk of 15-25% (3). Several small 
studies have explored the effects of alterations to the 
administration route, dose, total amount, frequency, 
and duration of HBIG treatment while incorporating the 
use of oral antiviral agents with nucleos(t)ide analogue 
therapy (NAT) (4-7). The transition from HBIG to NAT 
would provide a significant reduction in the costs, side 
effects, and inconveniences that are associated with 
HBIG, without sacrificing efficacy. 
2. Objectives
The purpose of this study was to examine the efficacy 
of NAT with minimal or no HBIG in preventing HBV 
recurrence after LT in a relatively large number of 
patients. 
3. Patients and Methods 
We reviewed the medical records of all patients with 
hepatitis B who underwent liver transplantation between 
2002 and 2007 at Rush University Medical Center in 
Chicago, Illinois. Hepatitis B diagnosis was defined by a 
positive HBV surface antigen (HBsAg) and HBV DNA. HBV 
patients undergoing liver transplantation for fulminant 
hepatic failure, hepatocellular carcinoma, and end 
stage liver disease were included. Patients co-infected 
with hepatitis C (HCV), hepatitis D (HDV), or human 
immunodeficiency virus (HIV) were also included in our 
analysis. Patients who suffered peri-operative death and 
did not receive HBIG or antiviral therapy were excluded 
from analysis. 
The following data were obtained for each patient: 
1) Clinical information- gender, age, ethnicity/race; 
date, indication for transplantation, Model for End stage 
Liver Disease (MELD) score at transplantation; follow-up 
time, time to HBV recurrence, graft and patient survival, 
re-transplantation, and cause of death.
2) Virological and serological data- pre-LT HBsAg, HBV 
e antigen, HBV e antibody, HBV DNA, HCV antibody, HCV 
RNA, HDV antibody, HIV antibody, liver function tests; 
post-LT HBsAg and HBV DNA, liver function tests.
3) Treatment- pre-LT antiviral NAT regimen, post-
LT NAT regimen, HBIG prophylaxis regimen, post-LT 
immunosuppression, adverse reactions and compliance 
to NAT. Resistance testing for mutations, including the 
YMDD mutation, was not universally obtained.
The primary endpoint of this study was HBV recurrence, 
as defined by a positive test for HBV DNA in the blood. 
The secondary endpoints included the safety of NAT and 
the survival of grafts and patients. 
3.1. Anti HBV Therapy
We noted the pre-transplant antiviral treatment 
regimen for each patient, including drug, dose, 
frequency, and duration of treatment. Patients were 
divided into 3 groups based on HBIG utilization. Group 
1 received no HBIG. Group 2 received only inpatient HBIG 
daily for up to 7 days. Group 3 received inpatient HBIG 
daily for up to 7 days and outpatient HBIG monthly for 
up to 6 months. In all cases, the HBIG dose was 10,000 
IU given intravenously. All patients received post-LT 
NAT of lamivudine, adefovir, or tenofovir, either singly 
or in combination. The differences in anti-HBV therapy 
reflected the evolving use of HBIG and NAT by the 
transplant team between 2002 and 2007. In general, 
more HBIG was used in 2002 and less or no HBIG was 
used in 2007.
3.2. Immunosuppressive Therapy
Patients were maintained on a standard 
immunosuppressive regimen with calcineurin inhibitor-
based therapy (tacrolimus or cyclosporine). The doses of 
calcineurin inhibitors were adjusted based on tacrolimus 
and cyclosporine levels. Corticosteroids were used for 
immunosuppression induction and typically were 
tapered off by 6 months post liver transplantation. Any 
acute cellular rejection was confirmed by liver biopsy 
and treated with corticosteroid boluses.
3.3. Clinical Follow-up
Standard hematological, biochemical, and HBV 
serological and virological testing was performed 
regularly after transplantation. After 2006, HBV DNA 
testing was performed using Versant HBV 3.0 bDNA 
Assays (Bayer Health Care LLC, Tarrytown, NY). Prior 
to 2006, HBV DNA testing was performed using Roche 
HBV DNA Quantitation Kits (Roche Molecular Systems, 
Branchburg, NJ). Testing for the presence of HBV mutants 
was not routinely performed. Liver biopsy was obtained 
as clinically indicated for investigation of elevated liver 
function tests or for evaluation of graft dysfunction. 
Histological evaluation included immunohistochemical 
staining for HBsAg and HBV core antigen. Compliance 
was assessed by whether patients returned for clinical 
follow-up visits, refilled NAT prescriptions, and reported 
the use of NAT during clinic visits, as recorded in the 
medication lists of their clinical records.
3.4. Statistical Analysis
All data entry and collection was performed using 
Microsoft Excel 2003 (Microsoft). Statistical analysis was 
performed using SAS 8.2 (SAS Institute Inc.). We used 
Chi-square tests and Wilcoxon tests to compare patient 
groups. Approval from the institutional review board 
at Rush University Medical Center was obtained for the 
study.
 Hepat Mon. 2011;11(8):638-645
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4. Results
4.1. Patient Characteristics
32 of the 525 (6.1%) liver transplants performed between 
2002 and 2007 at Rush University Medical Center in 
Chicago, Illinois were for HBV. Four patients who died peri-
operatively and did not receive HBIG were excluded from 
analysis. Baseline characteristics are shown in Table 1. Two 
patients in group 2 had undetectable HBsAg but positive 
HBV DNA pre- LT. Eighteen of the patients included in the 
study (64%) were men, and 13 (47%) were white. Patients 
had a median age of 54.5 years. Of the 28 patients, 26 had 
cirrhosis, 9 had concomitant hepatocellular carcinoma, 
and 2 presented with fulminant hepatic failure. Group 
1 comprised 4 patients who received no HBIG. Group 2 
included 6 patients who received only daily inpatient 
HBIG. Group 3 comprised 18 patients who received daily 
inpatient HBIG for up to 7 days and monthly outpatient 
HBIG for up to 6 months. 
4.2. HBV Prophylaxis 
18 patients (64%) received antiviral treatment with NAT 
prior to LT. Table 2 outlines the treatment characteristics. 
Prior to LT, 1 of the 4 patients in Group 1 had been on 
antiviral treatment for 2 months, 4 of the 6 patients in 
Group 2 had been on antiviral treatment for a median of 
8.7 months (range 3–26.3 months), and 13 of the 18 patients 
in Group 3 had been on antiviral treatment for a median 
of 4.1 months (range 0.2–16.8 months). Pre-LT treatment 
for 13 of the 28 patients (46%) included monotherapy 
with lamivudine (12/13) or entecavir (1/13) for a median 
of 2.7 months (range 0.2–26.3 months), while 5 patients 
(18%) received a combination of antiviral medications (4 
on lamivudine 100 to 150 mg and adefovir 10 mg daily, 
1 on entecavir 0.5 mg and adefovir 10 mg daily) for a 
median of 12.7 months (range 4.3–16.8) before LT. All 
HBIG doses were 10,000 IU given intravenously. Group 
1 received no HBIG. Group 2 received daily inpatient 
doses of HBIG for an average of 4 days and no outpatient 
monthly HBIG. Group 3 received daily inpatient doses of 
HBIG for an average of 7 days and monthly outpatient 
doses of HBIG for an average of 6 months. After LT, 3 
patients in Group 1 received monotherapy with entecavir, 
lamivudine or adefovir and 1 patient in Group 1 received 
a combination of lamivudine and adefovir. In Group 2, 5 
patients were treated with a combination of lamivudine 
and adefovir and 1 patient was treated with lamivudine 
alone. In Group 3, 9 patients received combination NAT 
consisting of lamivudine and adefovir, 1 patient received 
Group 1, 
No HBIG 
(n = 4)
Group 2, 
Inpatient HBIG 
(n = 6) 
Group 3, Inpatient and 
Outpatient HBIG 
(n = 18) 
P value
Total 
(n = 28)
Gender, M a/F a 2/2 3/3 13/5 18/10  0.447
Age, y, median (range) 57 (43-73) 62 (47-71) 53 (39-72) 54.5 (39-73) 0.209
Ethnicity, No. (%) 0.459
Asians
African-Americans
Hispanic
White
0 (0)
0 (0)
2 (50)
2 (50)
1 (16)
2 (33)
0 (0)
3 (50)
5 (28)
3 (16)
2 (11)
8 (44)
6 (21)
5 (18)
4 (14)
13 (46)
Indication for LT, No. (%)
Cirrhosis
Liver Cancer
Fulminant hepatic         
failure
4 (100)
2 (50)
0 (0)
6 (100)
2 (33)
0 (0)
16 (89)
5 (28)
2 (11)
26 (93)
9 (32)
2 (7)
0.405
0.839
1
MELD a, mean score 19 22 22 21.9 0.93
sAg, No. (%) 4 (100) 4 (67) 18 (100) 26 (93)
eAg, No. (%) 2 (50) 2 (33) 8 (44) 12 (43)
eAb, No. (%) 1 (25) 4 (67) 7 (39) 12 (43)
HBV DNA (+) at time of 
NATa initiation, No. (%)
1 (25) 3 (50) 14 (78) 18 (64)
DNA level, IU/L, median 2230 179 
(range 179 to 1 × 107)
25,375 
(range 20 to 1 × 107)
23200
(range 20 to 1 × 107)
0.743
HCV Ab (+), No. (%) 2 (50) 1 (16) 1 (6) 4 (14) 0.063
HDV Ab (+), No. (%) 0 (0) 0 (0) 3 (17) 3 (11)
HIV Ab (+), No. (%) 1 (25) 0 (0) 0 (0) 1 (4) 0.115
Table 1. Baseline Characteristics
a Abbreviations: F, female; LT, liver transplantation; M, male; MELD, model for end stage liver disease; NAT, nucleos(t)ide analogue therapyHepat Mon. 2011;11(8):638-645
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a combination of emcitritabine and tenofovir, and 8 
patients received lamivudine monotherapy. 
4.3. HBV Recurrence
Four of the 28 patients included in the study (14%) had 
HBV recurrence with positive HBsAg and a median HBV 
DNA of 9.4 × 106 IU/ml. Median time to HBV recurrence was 
15.5 months (range 9.9–24.3 months). Table 3 outlines the 
risk factors for HBV recurrence. The median pre-LT HBV 
DNA for patients with HBV recurrence was 1.7 × 106 IU/ml 
(range 7.1 × 105 to 2.5 × 106 IU/ml) versus 8113 IU/ml (range 
20 to 1 × 107 IU/ml) for patients without HBV recurrence (P 
= 0.21). After LT, 3 of the 4 patients with HBV recurrence 
had been prescribed a combination of lamivudine 
and adefovir, and 1 patient was prescribed adefovir 
monotherapy. HBV mutation testing for NAT resistance 
was not available for these patients. All four patients with 
HBV recurrence had been noncompliant with prescribed 
antiviral treatment and follow-up. One patient did not 
return for any follow-up visits for 10 months. During that 
time, she did not take her NAT. A second patient was lost 
to follow-up for 9 months during which time he did not 
take his NAT. A third patient admitted to not taking her 
NAT when she was diagnosed with HBV recurrence. The 
fourth patient indicated that she did not take her NAT 
due to financial difficulties and was lost to follow-up for 
21 months. When she returned for follow-up care, she 
was diagnosed with HBV recurrence.
24 of the 28 patients studied (86%) did not have 
recurrence, with negative HBV DNA at a median of 35.2 
months post-LT (range 3.4–58 months). All 24 were 
compliant with the prescribed antiviral therapy and 
clinical follow-up. 13 of the 24 patients without HBV 
recurrence (54%) received combination NAT, with 12 
receiving lamivudine and adefovir and 1 receiving 
emcitritabine and tenofovir. The remainder (11/24, 
46%) received NAT monotherapy, with 10 receiving 
lamivudine and 1 receiving tenofovir. In Group 1, 1 of the 
4 patients (25%) experienced HBV recurrence. In Group 2, 
no patients experienced HBV recurrence and in Group 
3, 3 of the 18 patients (17%) experienced HBV recurrence. 
There were no statistical differences in recurrence with 
respect to HBIG prophylaxis (P = 0.15) There were also 
no differences in recurrence with respect to post-LT 
combination NAT (P = 0.19), post-LT NAT monotherapy 
(P = 0.17), or to pre-LT DNA levels (P = 0.21). Recurrence 
occurred only in patients who did not comply with the 
prescribed HBV prophylaxis regimen (P < 0.0001). The 
time between LT and recurrence was longer in Group 3 
than in Group 1 (P = 0.029). All cases of HBV recurrence 
were effectively treated with combination NAT, all 4 
patients with HBV recurrence were alive at follow-up a 
median 42.2 months after LT, and none of these patients 
experienced graft loss. Figure 1 provides an outline of 
patient outcomes. 
Group 1, 
No HBIG 
(n = 4) 
Group 2, 
Inpatient HBIG 
(n = 6) 
Group 3, Inpatient and 
outpatient HBIG 
(n = 18) 
Total 
(n = 28)
Pre-LT a antiviral therapy, No. (%) 1 (25) 4 (67) 13 (72) 18 (64)
Monotherapy, No. (%)
Lamivudine, No. (%)
Entecavir, No. (%)
Combination therapy, No. (%)
Lamivudine + Adefovir, No. (%)
Entecavir + Adefovir, No. (%)
Pre-LT Rx b duration, median mo. 
(range)
1 (25)
1 (25)
0 (0)
0 (0)
0 (0)
0 (0)
2
3 (50)
1 (16)
2 (33)
1 (16)
0 (0)
1 (16)
8.7 (3–26.3)
9 (50)
9 (50)
0 (0)
4 (22)
4 (22)
0 (0)
4.1 (0.2–16.8)
13 (46)
11 (39)
2 (7)
5 (18)
4 (14)
1 (4)
4.2 (0.2–26.3)
HBIG a, 10,000 IU/IV dose        
Inpatient, daily, mean No. doses
Outpatient, monthly, mean No. 
doses
0
0
4
0
7
6
5.1
3.5
Post-LT Antiviral Therapy        
Monotherapy, No. (%)
Lamivudine
Adefovir
Tenofovir
Combination therapy, No. (%)
Lamivudine + Adefovir
Emcitritabine + Tenofovir
3 (75)
1 (25)
1 (25)
1 (25)
1 (25)
1 (25)
0 (0)
1 (16)
1 (16)
0 (0)
0 (0)
5 (83)
5 (83)
0 (0)
8 (44)
8 (44)
0 (0)
0 (0)
10 (56)
9 (50)
1 (6)
12 (43)
10 (36)
1 (4)
1 (4)
16 (57)
15 (54)
1 (4)
Table 2. Treatment Characteristics
a Abbreviations: HBIG, hepatitis B immunoglobulin; LT, liver transplantation
b Rx, treatmentHepat Mon. 2011;11(8):638-645
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4.4. Survival
Outcomes for patients in each HBIG group are 
shown in Table 4. Patients were followed for a median 
of 35.2 months (range 3.4–57.5 months). There were no 
differences between the 3 HBIG groups in time followed 
(P = 0.058), graft loss (P = 0.284), or death (P = 0.143). A 
total of 3 patients (14%) suffered graft loss unrelated to 
HBV recurrence; 1 due to primary nonfunction and 2 due 
to biliary cast syndrome. These 3 patients underwent 
repeat LT at a median of 99 days after the initial LT 
(range 19–366 days). There was 1 death unrelated to HBV 
recurrence that was due to cerebrovascular accident 306 
days after LT.
4.5. Adverse Events and Safety
There were no reports of significant adverse events 
associated with HBIG use. There were no reports of 
significant adverse events associated with NAT. There was 
no new diagnosis of renal insufficiency or any worsening 
underlying renal insufficiency associated with antiviral 
treatment. Ten of the 16 patients (63%) on combination 
NAT had underlying chronic insufficiency with resultant 
renal-adjusted dosing. 
 5. Discussion
Although the mechanism of HBIG in preventing 
HBV recurrence post-LT is not fully understood, its 
ability to prevent recurrence in 75% to 85% of patients 
transformed HBV from a contraindication to a readily 
accepted indication for LT worldwide (2, 3, 8). However, 
the use of HBIG has been limited due to its indefinite use, 
significant cost, parenteral administration, persistent 
risk of recurrence, and development of HBV surface 
antigen (HBsAg) escape mutations (3, 9-11). Adverse 
effects include headaches, myalgias, flushing, pain, and 
Recurrence 
(n = 4)
Non-recurrence 
(n = 24)
Total 
(n = 28)
P value
Pre-LT antiviral therapy, No. (%) 2 (50) 16 (67) 18 (64) 1
Combination, No. (%)
Monotherapy, No. (%)
Duration of Rx a, median mo. 
0 (0)
2 (50)
2
5 (21)
11 (46)
2
5 (18)
13 (46)
2
1
1
0.341
Pre-LT DNA level, IU/L 1.7 × 106 
(range 7.1 × 10 5 to 2.5 × 10 6)
8113 
(range 20 to 1 × 10 7)
23200
(range 20 to 1 × 10 7)
0.213
HBIG Group
Group 1, No. (%)
Group 2, No. (%)
Group 3, No. (%)
Noncompliance, No. (%)
1 (25)
0 (0)
3 (75)
4 (100)
 3 (12)
6 (25)
15 (63)
0 (0)
 
4 (14)
6 (22)
18 (64)
4 (14)
0.581
 
 
 
< 0.0001
Post-LT Antiviral Therapy        
Monotherapy, No. (%)
Lamivudine
Adefovir
Tenofovir
Combination therapy, No. (%)
Lamivudine + Adefovir
Emcitritabine + Tenofovir
1 (25)
0 (0)
1 (25)
0 (0)
3 (75)
2 (50)
1 (25)
11 (46)
10 (42)
0 (0)
1 (4)
13 (54)
13 (54)
0 (0)
12 (43)
10 (36)
1 (4)
1 (4)
16 (57)
15 (54)
1 (4)
0.1667
 
 
 
0.1875
 
 
Table 3. Risk Factors for Recurrence
a Rx, treatment
Group 1, 
No HBIG a 
(n = 4) 
Group 2,  Inpatient 
HBIG 
(n = 6) 
Group 3,  Inpatient and 
outpatient HBIG 
(n = 18) 
Total 
(n = 28)
P value
Recurrence, No. (%)  1 (25) 0 (0) 3 (17) 4 (14) 0.581
Recur., median mo. 
(range)
9.9 NA 21 (8.8–24.4) 15.5 (8.8–24.4) 0.029
Follow up, median mo. 
(range)
16.8 (3.4–47.9) 23 (13.8–57.2) 42.9 (19.3–57.5) 35.2 (3.4–57.5) 0.0579
Death, No. (%) 1 (25) 0 (0) 0 (0) 1 (4) 0.143
Graft loss and repeat 
Transplantation, No.(%)
1 (25) 1 (16) 1 (6) 3 (14) 0.284
Table 4. Outcome
a Abbreviations: HBIG, hepatitis B immunoglobulinHepat Mon. 2011;11(8):638-645
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even reports of mercury poisoning (12). These limitations 
of HBIG have pushed investigators to explore lower cost 
and more effective alternatives to prevent post-LT HBV 
recurrence. These have included adjusting HBIG doses 
based on the HBV surface antibody titer, intramuscular 
administration of HBIG, and HBIG treatment of finite 
duration (4, 5, 8). Oral antiviral therapy with NAT offered 
an alternative to the costs and side effects associated 
with HBIG when lamivudine became available in 1995. 
However, the elevated risk of HBV recurrence with 
lamivudine monotherapy became apparent when initial 
reports of less than 10% HBV recurrence at 1 year were 
followed by reports of 45% recurrence at 3 years, due to 
the development of the YMDD mutation (13, 14). 
The next phase in HBV recurrence prophylaxis was the 
combination of lamivudine with HBIG. Markowitz et al. 
reported that 14 patients who received lamivudine and 
high-dose IV HBIG had no recurrence at 13.2 months (15). 
Yao et al. were able to convert 10 patients on lamivudine 
from high-dose IV HBIG to IM HBIG, with only 1 HBV 
recurrence due to noncompliance 15.6 months after 
the change was made (16). Other researchers using 
combination HBIG and lamivudine reported a lower 
than 10% risk of HBV recurrence more than 3 years after 
LT (17, 18). Several small studies have evaluated the use of 
newer NAT with and without HBIG in preventing post-
LT HBV recurrence. Nath et al. reported that 14 patients 
who received 7 days of high-dose IV HBIG with tenofovir 
or lamivudine and adefovir experienced no clinically 
significant HBV recurrence (7). Schiff et al. more recently 
reported that 23 patients who received lamivudine and 
adefovir before and after LT without HBIG experienced 
no HBV recurrence during 9 months of follow-up (19). 
Neff  et al. reported that 10 patients on combination 
lamivudine and adefovir had no HBV recurrence at a 
mean of 31 months after discontinuing high-dose IV 
HBIG (20). Marzano et al. reported that only 4 of 99 
patients who received a combination of lamivudine 
and adefovir with high-dose intravenous HBIG for an 
indefinite period of time experienced HBV recurrence. 
Two of the 4 patients with recurrence in that study were 
noncompliant with NAT (6). In addition, Gane et al. 
reported no HBV recurrence at a median of 11.7 months 
in 19 patients who received combination lamivudine 
and adefovir and only 7 days of IM HBIG (4). Angus et al. 
reported the safe elimination of low dose, IM HBIG 12 
months after LT with continuation of lamivudine and 
adefovir (5). No patients had recurrent HBV DNA but 
one patient became HBsAg positive. There have been 
more recent studies reporting discontinuation of HBIG 
in selected patients, but the number of patients in these 
reports was limited. Noncompliance has been associated 
with HBV recurrence in several studies (16, 21-24). 
The optimal NAT regimen (monotherapy versus 
combination therapy) remains undefined. In our study, 
NAT with no HBIG or a short course of high-dose (10,000 
IU) intravenous HBIG lasting between 1 week and 6 
months was efficacious and safe. Only 4 of 28 patients 
(14%) had HBV recurrence a median 35 months after LT, 
and none of these were compliant with the prescribed 
treatment regimen. These 4 patients show that the risk of 
recurrence when patients are treated with combination 
NAT and minimal HBIG is still greater than zero (5-7, 19). 
Noncompliance with HBV prophylaxis seems to be the 
Figure 1. HBV Liver Transplant Patient OutcomesHepat Mon. 2011;11(8):638-645
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common factor associated with HBV recurrence across 
studies, and it was the only statistically significant 
predictor of HBV recurrence in our study (P < 0.0001). 
Although complete compliance to NAT utilization 
cannot be proven in patients without HBV recurrence, 
these patients had documented return clinical visits, 
NAT prescription renewals, and reported NAT utilization, 
unlike the patients with HBV recurrence, none of whom 
fulfilled any of these criteria. 
Despite not reaching statistical significance, the 4 
patients in our study with HBV recurrence had a higher 
median HBV DNA level at the time of LT (P > 0.20). With 
a larger sample size, these factors might have reached 
statistical significance. Recurrent HBV was successfully 
controlled in all 4 patients by re-initiating combination 
NAT. With regard to the secondary endpoints of the study, 
each of the HBIG groups had 1 graft loss unrelated to HBV 
recurrence, and 1 patient in Group 1 (no HBIG) died due 
to a cerebrovascular accident that was also unrelated 
to HBV recurrence. Previous studies have been limited 
in sample size and duration of the follow-up period. 
Meta-analyses and reviews of the literature on this topic 
have been limited to studies that have mainly utilized 
HBIG and lamivudine. Compared to earlier studies, the 
current study has the advantage of larger size, longer 
follow-up, shorter duration of HBIG administration, 
inclusion of treatment regimens that include no HBIG, 
and the inclusion of more than 1 type of NAT. Schiff et 
al. (19) included more patients who received no HBIG or 
only inpatient HBIG than our study did, but our study 
had a much longer follow-up time of 16.8 months for the 
no HBIG group (Group 1) and 23 months for the inpatient 
HBIG only group (Group 2). Our study also presents data 
on a larger number of patients (18) who received up to 6 
months of monthly outpatient HBIG who were followed 
for a longer duration (a median of 42.9 months) as 
compared to the Schiff et al. paper. 
Our study is limited, because it was a retrospective 
study of a heterogeneous group of patients from a single 
tertiary care center. In addition, the HBV prophylaxis 
regimen reflected a change in practice patterns over 
time, which was reviewed in a retrospective manner 
rather than determined in a prospective fashion. Finally, 
mutation testing was not routinely performed making 
those results unavailable. In conclusion, this study 
demonstrates that antiviral NAT with no or minimal 
HBIG is effective and safe in preventing HBV recurrence 
for up to 35 months after LT, provided that patients are 
compliant with antiviral therapy and follow-up care. The 
current study takes a definitive step forward in making 
the case for limiting HBIG to 1 week or eliminating its use 
when combination NAT is prescribed. Further study is 
needed, however, ideally in the context of a multi-center 
collaborative study.
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